LYN and Chronic Eosinophilic Leukemia, Not Otherwise Specified: Recent reports show that dasatinib, a double inhibitor for Lyn and PDGFRA kinase, have the same or even more effectiveness than imatinib in F/P-positive CEL [14, 45–47].